GlassScriptPhysician profile
Avinash N Ramchandani
NPI 1730358532
$15,250.71
in general payments reported to CMS, 2019-2025
19 companies · $904 in 2025
The $904 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $584 · 2021: $1,064 · 2022: $65.87 · 2023: $298 · 2024: $836 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,642 · Travel and Lodging: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,641.73 |
| Travel and Lodging | $395.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $8,464.96 | 2019-2024 | Intracept |
| Nevro Corp. | $1,987.19 | 2019-2024 | Senza |
| Medtronic, INC. | $1,486.83 | 2021-2025 | Synchromedii, Inceptiv, Intellis Adaptivestim |
| Medtronic USA, INC. | $1,376.57 | 2019 | |
| Abbott Laboratories | $894.40 | 2019-2025 | Eterna, Proclaim |
| Spr Therapeutics, INC | $439.11 | 2025 | Sprint Pns System |
| Scilex Pharmaceuticals INC. | $114.69 | 2019-2025 | Ztlido |
| Tersera Therapeutics LLC | $84.90 | 2019-2023 | Prialt |
| Vertiflex, INC. | $75.00 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $73.46 | 2025 | |
| Collegium Pharmaceutical, INC. | $48.30 | 2023-2024 | Belbuca |
| Averitas Pharma INC. | $37.80 | 2025 | Qutenza |
| Medtronic Vascular, INC. | $37.50 | 2019 | |
| Amgen INC. | $23.75 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $23.20 | 2023 | Iovera, Zilretta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $21.65 | 2024 | Euflexxa |
| Ibsa Pharma INC. | $21.57 | 2024 | Tirosint, Licart |
| Curonix LLC | $21.42 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Revance Therapeutics, INC. | $18.41 | 2025 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avinash Ramchandani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.